Internationally published, head-to-head data from india of petros pharmaceuticals' stendra(r) (avanafil) tablets reported improvement in erectile function compared to sildenafil and baseline after 12 weeks of therapy

Data published in the "international journal of urology" also showed secondary endpoints, such as onset of action in 15 minutes and percentage of patients reaching normal erectile function according to the iief-ef score new york, ny / accesswire / september 8, 2022 / petros pharmaceuticals, inc. (nasdaq:ptpi), a leading provider of therapeutics for men's health, today announces newly published third party data in the international journal of urology efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction by kumar, pathade, gupta, goyal, rath, thakre, sanmukhani, and mittal, detailing the company's pde 5 inhibitor stendra® (avanafil) tablets in a non-inferiority, head-to-head study compared to sildenafil (viagra) which was conducted in india. the primary efficacy endpoint was improvement in erectile function based on domain score of the international index of erectile function (iief).
PTPI Ratings Summary
PTPI Quant Ranking